DAVID SIMONS: Open Payments
NPI 1851634653 · GREENWOOD, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$965 in 46 payments from 11 companies in 2025. Trend: 2023 $209 · 2024 $206 · 2025 $965
Food & beverage: $965
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 14 | $247 |
| ABBVIE INC. | 10 | $155 |
| Janssen Pharmaceuticals, Inc | 5 | $125 |
| Neuronetics, Inc. | 1 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $88 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $82 |
| Axsome Therapeutics, Inc. | 3 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Lundbeck LLC | 1 | $33 |
| ACADIA Pharmaceuticals Inc | 1 | $22 |
Products named: INGREZZA, VRAYLAR, SPRAVATO, NEUROSTAR TMS THERAPY SYSTEM, TRINTELLIX, CAPLYTA, Auvelity, HETLIOZ.
Industry payments across SC — which companies pay providers there.
